Carrick NewsroomPress Releases

Saama Expands Leadership Team With Addition Of Visionary Medical Affairs Expert Kenneth L. Massey, Pharm.D.

CAMPBELL, CA (April 02, 2018)— Saama Technologies, Inc., a leading clinical data analytics company, today announced that Kenneth L. Massey, Pharm.D., one of the foremost medical affairs professionals in the life sciences industry, has joined the company in the key position of Chief Life Sciences Officer. Ken brings 30 years of medical affairs and drug development experience at leading global pharmaceutical companies to his new role at Saama.

As Chief Life Sciences Officer, Ken will be responsible for driving market leadership for Saama’s award-winning life sciences data analytics solutions. Ken will oversee pre-Phase 1 through Phase 3-plus clinical development, identifying and activating opportunities for emerging and existing clients to leverage Saama’s Clinical Analytics Platform to successfully launch critical new therapies into the marketplace.

“Saama truly believes that data and analytics will play a critical role in transforming the overall life sciences industry to the benefit of humanity, and we are confident that Ken will help Saama lead this revolution,” said Suresh Katta, Founder and CEO of Saama Technologies. “Ken’s decades of strategic medical affairs expertise and clinical experience will further enhance our platform’s ability to leverage Artificial Intelligence and Deep Learning to enable life sciences companies to optimize the cycle time, cost, and outcomes of their critical clinical development business processes.”

“Saama’s positive disruption of the life sciences industry is extremely impressive and signals a new era in clinical development opportunities,” said Ken. “I am excited to apply my pharmaceutical, clinical, and academic acumen to enhancing Saama’s growth, distinguishing its unique platform and suite of products, and expanding its leadership position in today’s dynamic healthcare environment.”

Ken joins Saama from Merck & Company, where he served as Vice President, Medical Affairs for the past five years. At Merck, Ken was responsible for all aspects of strategic planning, governance and management of the U.S. Medical Affairs organization. Ken’s extensive experience creating, developing and leading medical affairs organizations at any point along the organizational continuum and across a full range of therapeutic areas was additionally demonstrated during prior tenures at Novartis and Mitsubishi Tanabe Pharma America, where he spent a combined total of 13 years.

Ken has received numerous awards and honors, including the inaugural Novartis CEO’s Diversity and Inclusion Award, which recognizes individuals and teams committed to integrating diversity and inclusion principles with business practices. Ken is widely published in leading industry and professional society journals on a range of clinical, pharmacological and therapeutic topics. Ken received both his Bachelor of Science in Pharmacy and his Doctor of Pharmacy from the University of Florida Gainesville College of Pharmacy.

About Saama

Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences and the Global 2000. Saama is singularly focused on driving fast, flexible, impactful business outcomes for its clients through advanced data and analytics. Saama’s unique “hybrid” approach integrates focused solutions and expertise across the life sciences domain, business consulting, machine learning, automated data management, cloud and big data technologies. Saama’s approach integrates manual and disconnected data initiatives into a well-aligned roadmap facilitating the client’s journey from strategy through solution implementation to generate business

About Carrick Capital Partners
Who We Are
A firm of enterprise software, SaaS, and technology enabled services investors and operating executives with substantial experience founding, scaling, and optimizing market leading businesses.
Our Approach
We work with management to identify and improve critical areas of their business - focusing on the priorities that align with our experiences and that will deliver the highest strategic impact in both the short-term and long-run.
Why We Are Different
We have a concentrated number of companies in our portfolio so that we can build substantial relationships with each management team and ensure our firm's commitment to each company's goals.
Latest News
Saviynt Logo.jpg
Los Angeles, CA (October 14, 2019) - Saviynt (www.saviynt.com), one of Inc. Magazine’ 5000 fastest growing companies in the US and thought leader in converging Identity Governance and Cloud Privileged Access Management solutions today announced that the company has once again been named a Leader in the 2019 Magic Quadrant for Identity Governance and Administration[1] report by analysts Felix Gaehtgens, Kevin Kampman, Abhyuday Data, Henrique Teixeira, and David Collinson.
October 14, 2019
Accolade Logo.jpg
Strategic Investment from Humana Designed to Strengthen and Expand the Integrated Offering from Accolade and Humana
October 10, 2019
Saviynt Logo.jpg
By extending their solutions and services portfolio with Saviynt, iC Consult Group expands its offering in the areas of Identity Management and Governance, Application Risk and Compliance Governance and Identity-centric Cloud Security
October 8, 2019